Healthcare Public Relations & Strategic Communications

Healthcare is the most regulated communications environment in public relations, and the rules are not optional. Every promotional claim about a drug or device must carry fair balance under FDA guidance—benefits cannot be stated without the corresponding risks—and off-label promotion carries real legal exposure. Payments to physicians are reported publicly under the Sunshine Act, medical publications follow ICMJE authorship and disclosure standards, and interactions with journals are governed by strict embargo conventions. A healthcare PR program that treats these as afterthoughts does not just underperform; it creates liability.

That regulatory reality shapes everything downstream. A clinical data readout is not a product announcement—it is a coordinated event where the abstract, the journal embargo, the investor-disclosure obligations, and the media strategy all have to move in lockstep, often to the minute. A pharmaceutical launch is gated by FDA approval timing that no communications calendar controls. Thought leadership for a chief medical officer has to survive medical, legal, and regulatory (MLR) review before it ever reaches a reporter. The organizations that win coverage are the ones whose communications team understands the science well enough to translate it accurately and the rules well enough to move fast within them.

AMW's healthcare practice works across the sector's distinct audiences—patients, providers, and payers—because a message that resonates with a patient-advocacy community will not move a formulary decision, and a clinical narrative built for physicians will not reassure a worried caregiver. We build communications for pharmaceutical and biotech companies, medical device manufacturers, health systems, and digital health innovators, and we structure each program around the specific regulatory pathway, evidence base, and stakeholder map of the organization in front of us.

The work spans the full lifecycle: building a scientific narrative ahead of a data readout, coordinating a launch around an FDA decision date, developing key opinion leader (KOL) and medical-affairs communications, engaging patient-advocacy groups substantively rather than transactionally, and preparing for the situations no one wants but every healthcare organization eventually faces—a safety signal, a recall, a pricing controversy, or a trial that misses its endpoint. In each case the goal is the same: accurate, compliant communication that holds up under scrutiny and builds durable trust rather than a short-term news hit.